
Joseph Pape
Examiner (ID: 18031, Phone: (571)272-6664 , Office: P/3612 )
| Most Active Art Unit | 3612 |
| Art Unit(s) | 2899, 3102, 3612 |
| Total Applications | 4170 |
| Issued Applications | 3665 |
| Pending Applications | 184 |
| Abandoned Applications | 378 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16824261
[patent_doc_number] => 20210139554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
[patent_app_type] => utility
[patent_app_number] => 17/065395
[patent_app_country] => US
[patent_app_date] => 2020-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -125
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065395
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/065395 | Interleukin-2 muteins for the expansion of T-regulatory cells | Oct 6, 2020 | Issued |
Array
(
[id] => 16727850
[patent_doc_number] => 20210094997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
[patent_app_type] => utility
[patent_app_number] => 17/063566
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18544
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063566
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/063566 | Interleukin-2 muteins for the expansion of T-regulatory cells | Oct 4, 2020 | Issued |
Array
(
[id] => 18685195
[patent_doc_number] => 11780913
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => IL-1b neutralizing human monoclonal antibodies
[patent_app_type] => utility
[patent_app_number] => 17/061194
[patent_app_country] => US
[patent_app_date] => 2020-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 17
[patent_no_of_words] => 10130
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061194
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/061194 | IL-1b neutralizing human monoclonal antibodies | Sep 30, 2020 | Issued |
Array
(
[id] => 18492272
[patent_doc_number] => 11697683
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Anti-IL31 antibodies for veterinary use
[patent_app_type] => utility
[patent_app_number] => 17/039495
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 13
[patent_no_of_words] => 16300
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039495
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/039495 | Anti-IL31 antibodies for veterinary use | Sep 29, 2020 | Issued |
Array
(
[id] => 18004987
[patent_doc_number] => 20220363753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ANTI-TIRC7 ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/765267
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/765267 | Anti-TIRC7 antigen binding proteins | Sep 29, 2020 | Issued |
Array
(
[id] => 18413173
[patent_doc_number] => 11667706
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Methods of purifying recombinant anti-abeta antibodies
[patent_app_type] => utility
[patent_app_number] => 17/031468
[patent_app_country] => US
[patent_app_date] => 2020-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 7
[patent_no_of_words] => 36782
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031468
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/031468 | Methods of purifying recombinant anti-abeta antibodies | Sep 23, 2020 | Issued |
Array
(
[id] => 17958677
[patent_doc_number] => 20220339257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => METHODS TO INCREASE THE SENSITIVITY AND REVERSING THE RESISTANCE TO DRUGS
[patent_app_type] => utility
[patent_app_number] => 17/761461
[patent_app_country] => US
[patent_app_date] => 2020-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761461
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/761461 | METHODS TO INCREASE THE SENSITIVITY AND REVERSING THE RESISTANCE TO DRUGS | Sep 16, 2020 | Abandoned |
Array
(
[id] => 18970297
[patent_doc_number] => 20240050389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 18/245157
[patent_app_country] => US
[patent_app_date] => 2020-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26477
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245157
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245157 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | Sep 14, 2020 | Pending |
Array
(
[id] => 16750946
[patent_doc_number] => 20210102955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
[patent_app_type] => utility
[patent_app_number] => 17/020325
[patent_app_country] => US
[patent_app_date] => 2020-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12304
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17020325
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/020325 | Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP) | Sep 13, 2020 | Abandoned |
Array
(
[id] => 18211359
[patent_doc_number] => 20230057622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => Recombinant Human Neuregulin Derivatives and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/642855
[patent_app_country] => US
[patent_app_date] => 2020-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10717
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642855 | Recombinant Human Neuregulin Derivatives and Use Thereof | Sep 13, 2020 | Pending |
Array
(
[id] => 18180915
[patent_doc_number] => 20230041644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/753692
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753692 | METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS | Sep 10, 2020 | Pending |
Array
(
[id] => 18180915
[patent_doc_number] => 20230041644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/753692
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753692 | METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS | Sep 10, 2020 | Pending |
Array
(
[id] => 18180915
[patent_doc_number] => 20230041644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/753692
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753692 | METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS | Sep 10, 2020 | Pending |
Array
(
[id] => 18180915
[patent_doc_number] => 20230041644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/753692
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/753692 | METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS | Sep 10, 2020 | Pending |
Array
(
[id] => 16657465
[patent_doc_number] => 20210054101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => ANTIBODIES TO MATRIX METALLOPROTEINASE 9
[patent_app_type] => utility
[patent_app_number] => 17/017491
[patent_app_country] => US
[patent_app_date] => 2020-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14764
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017491
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/017491 | Antibodies to matrix metalloproteinase 9 | Sep 9, 2020 | Issued |
Array
(
[id] => 16525256
[patent_doc_number] => 20200399336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => IL-21 (HETERODIMERIC FC-FUSED IL-21) FUSED TO IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION HETERODIMER (HETERODIMERIC FC), AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/015875
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015875
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/015875 | IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same | Sep 8, 2020 | Issued |
Array
(
[id] => 16621531
[patent_doc_number] => 20210040184
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => ANTI-HIV ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/015287
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015287
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/015287 | ANTI-HIV ANTIBODIES | Sep 8, 2020 | Abandoned |
Array
(
[id] => 17897053
[patent_doc_number] => 20220306715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => CHIMERIC PROTEINS IN AUTOIMMUNITY
[patent_app_type] => utility
[patent_app_number] => 17/638925
[patent_app_country] => US
[patent_app_date] => 2020-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 81583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -94
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638925
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/638925 | CHIMERIC PROTEINS IN AUTOIMMUNITY | Aug 27, 2020 | Abandoned |
Array
(
[id] => 16941073
[patent_doc_number] => 11053294
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-07-06
[patent_title] => Masked cytokine polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/002742
[patent_app_country] => US
[patent_app_date] => 2020-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 52
[patent_figures_cnt] => 132
[patent_no_of_words] => 157122
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002742
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/002742 | Masked cytokine polypeptides | Aug 24, 2020 | Issued |
Array
(
[id] => 16525258
[patent_doc_number] => 20200399338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => IL-15 Conjugates and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/001965
[patent_app_country] => US
[patent_app_date] => 2020-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40284
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -88
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001965
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/001965 | IL-15 conjugates and uses thereof | Aug 24, 2020 | Issued |